Literature DB >> 30204129

HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.

Yingying Wang1, Xiaoling Weng2, Luoyang Wang3, Mingang Hao4, Yue Li5, Lidan Hou6, Yu Liang6, Tianqi Wu2, Mengfei Yao2, Guowen Lin7, Yiwei Jiang8, Guohui Fu5, Zhaoyuan Hou1, Xiangjun Meng6, Jinsong Lu8, Jianhua Wang2,9.   

Abstract

Breast cancer (BrCa) is the malignant tumor that most seriously threatens female health; however, the molecular mechanism underlying its progression remains unclear. Here, we found that conditional deletion of hypermethylated in cancer 1 (HIC1) in the mouse mammary gland might contribute to premalignant transformation in the early stage of tumor formation. Moreover, the chemokine (C-X-C motif) ligand 14 (CXCL14) secreted by HIC1-deleted BrCa cells bound to its cognate receptor GPR85 on mammary fibroblasts in the microenvironment and was responsible for activating these fibroblasts via the ERK1/2, Akt, and neddylation pathways, whereas the activated fibroblasts promoted BrCa progression via the induction of epithelial-mesenchymal transition (EMT) by the C-C chemokine ligand 17 (CCL17)/CC chemokine receptor 4 (CCR4) axis. Finally, we confirmed that the HIC1-CXCL14-CCL17 loop was associated with the malignant progression of BrCa. Therefore, the crosstalk between HIC1-deleted BrCa cells and mammary fibroblasts might play a critical role in BrCa development. Exploring the progression of BrCa from the perspective of microenvironment will be beneficial for identifying the potential prognostic markers of breast tumor and providing more effective treatment strategies.

Entities:  

Keywords:  Breast cancer; Cell Biology; Chemokines; Oncology

Mesh:

Substances:

Year:  2018        PMID: 30204129      PMCID: PMC6264654          DOI: 10.1172/JCI99974

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling.

Authors:  Jinchang Lu; Guohui Song; Qinglian Tang; Changye Zou; Feng Han; Zhiqiang Zhao; Bicheng Yong; Junqiang Yin; Huaiyuan Xu; Xianbiao Xie; Tiebang Kang; YingLee Lam; Huiling Yang; Jingnan Shen; Jin Wang
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

4.  Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.

Authors:  Galina V Shurin; Robert L Ferris; Robert Ferris; Irina L Tourkova; Lori Perez; Anna Lokshin; Levent Balkir; Bobby Collins; Gurkamal S Chatta; Michael R Shurin
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

5.  The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4.

Authors:  T Imai; M Baba; M Nishimura; M Kakizaki; S Takagi; O Yoshie
Journal:  J Biol Chem       Date:  1997-06-06       Impact factor: 5.157

6.  A conserved mRNA expression profile of SREB2 (GPR85) in adult human, monkey, and rat forebrain.

Authors:  Mitsuyuki Matsumoto; Senda Beltaifa; Cynthia Shannon Weickert; Mary M Herman; Thomas M Hyde; Richard C Saunders; Barbara K Lipska; Daniel R Weinberger; Joel E Kleinman
Journal:  Brain Res Mol Brain Res       Date:  2005-07-29

7.  Expression of CXCL14 and its anticancer role in breast cancer.

Authors:  Xiao-Li Gu; Zhou-Luo Ou; Feng-Juan Lin; Xiao-Li Yang; Jian-Min Luo; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2012-08-22       Impact factor: 4.872

8.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

9.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.

Authors:  M M Wales; M A Biel; W el Deiry; B D Nelkin; J P Issa; W K Cavenee; S J Kuerbitz; S B Baylin
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

10.  Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation.

Authors:  Maria-Giuseppina Procopio; Csaba Laszlo; Dania Al Labban; Dong Eun Kim; Pino Bordignon; Seung-Hee Jo; Sandro Goruppi; Elena Menietti; Paola Ostano; Ugo Ala; Paolo Provero; Wolfram Hoetzenecker; Victor Neel; Witold W Kilarski; Melody A Swartz; Cathrin Brisken; Karine Lefort; G Paolo Dotto
Journal:  Nat Cell Biol       Date:  2015-08-24       Impact factor: 28.824

View more
  18 in total

1.  The transcription factor Hypermethylated in Cancer 1 (Hic1) regulates neural crest migration via interaction with Wnt signaling.

Authors:  Heather Ray; Chenbei Chang
Journal:  Dev Biol       Date:  2020-06-02       Impact factor: 3.582

Review 2.  The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Authors:  Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon
Journal:  Mol Carcinog       Date:  2020-03-24       Impact factor: 4.784

3.  FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis.

Authors:  Yujie Wang; Qi Sun; Ying Ye; Xiaoting Sun; Sisi Xie; Yuhang Zhan; Jian Song; Xiaoqin Fan; Bin Zhang; Ming Yang; Lei Lv; Kayoko Hosaka; Yunlong Yang; Guohui Nie
Journal:  JCI Insight       Date:  2022-05-23

4.  CXCL14 Maintains hESC Self-Renewal through Binding to IGF-1R and Activation of the IGF-1R Pathway.

Authors:  Chih-Lun Cheng; Shang-Chih Yang; Chien-Ying Lai; Cheng-Kai Wang; Ching-Fang Chang; Chun-Yu Lin; Wei-Ju Chen; Po-Yu Lin; Han-Chung Wu; Nianhan Ma; Frank Leigh Lu; Jean Lu
Journal:  Cells       Date:  2020-07-16       Impact factor: 6.600

Review 5.  Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies.

Authors:  Go J Yoshida; Arata Azuma; Yukiko Miura; Akira Orimo
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

6.  miR-128 Functions as an OncomiR for the Downregulation of HIC1 in Breast Cancer.

Authors:  Yan Li; Ying Wang; Xiabo Shen; Xinghua Han
Journal:  Front Pharmacol       Date:  2019-10-17       Impact factor: 5.810

Review 7.  The Roles of Stroma-Derived Chemokine in Different Stages of Cancer Metastases.

Authors:  Shahid Hussain; Bo Peng; Mathew Cherian; Jonathan W Song; Dinesh K Ahirwar; Ramesh K Ganju
Journal:  Front Immunol       Date:  2020-12-22       Impact factor: 7.561

8.  Association between HIC1 promoter methylation and solid tumor: A meta-analysis.

Authors:  Tie Zhao; Justice Afrifa; Dong Wang; Jingcui Yu
Journal:  EXCLI J       Date:  2020-04-07       Impact factor: 4.068

9.  Down-regulation of CCL17 in cancer-associated fibroblasts inhibits cell migration and invasion of breast cancer through ERK1/2 pathway.

Authors:  Junjie Li; Chunli Yang; Jingshi Yang; Liqun Zou
Journal:  Cancer Manag Res       Date:  2019-08-07       Impact factor: 3.989

10.  CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems.

Authors:  Ariadni Kouzeli; Paul J Collins; Mieke Metzemaekers; Max Meyrath; Martyna Szpakowska; Marc Artinger; Sofie Struyf; Paul Proost; Andy Chevigne; Daniel F Legler; Matthias Eberl; Bernhard Moser
Journal:  Front Immunol       Date:  2020-10-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.